---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-083523"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T11:53:56.745941+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atea appoints Howard Berman to board, authorizes $25M buyback after activist settlement

## Summary
- Howard H. Berman (Coya Therapeutics founder) appointed as Class III director effective after 2025 annual meeting; will serve as observer until then.
- Agreement with activist investors Bradley Radoff and Michael Torok: slate withdrawn, standstill and voting commitments through mid-2026.
- Franklin Berger will retire from board after his Class I term expires at 2027 annual meeting.
- Board authorized up to $25M share repurchase program; strategic alternatives review with Evercore ongoing.
- Preliminary cash, cash equivalents and marketable securities as of March 31, 2025: $425.4 million.

## SEC filing metadata
- accession: 0001193125-25-083523
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/0001193125-25-083523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/d915073d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-083523
- JSON: https://secwatch.observer/filing/0001193125-25-083523.json
- Plain text: https://secwatch.observer/filing/0001193125-25-083523.txt

## Key facts
- Executive change
  Howard H. Berman was appointed as Class III director at Atea Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On April 16, 2025, the Board appointed Howard H. Berman, Ph.D. as a Class III director of the Company, effective at the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/0001193125-25-083523-index.htm
- Executive change
  Franklin Berger departed as Class I director at Atea Pharmaceuticals, Inc..
  - Action: retire
  - Role: Class I director
  source text: In addition, on April 16, 2025, in connection with the Agreement, Franklin Berger informed the Board that he would retire following the end of his current term as a Class I director at the 2027 Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/0001193125-25-083523-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.